期刊文献+

氨磷汀对顺铂致肾功能异常患者再化疗的肾脏保护作用 被引量:5

Clinical Study of Protection of Amifostine for Patients with Cisplatin-induced Nephrotoxicity using Chemotherapy Again
下载PDF
导出
摘要 目的观察氨磷汀对顺铂(DDP)致肾功能异常患者再化疗的肾脏保护作用。方法对19例因DDP化疗致肾功能异常患者,再次应用含DDP方案化疗,静脉用DDP前30min加用氨磷汀250mg/m2,治疗前及治疗后不同时间分别测定血尿素氮、血肌酐值,观察肾功能的变化情况。结果19例患者,有效4例,稳定12例,进展3例,总有效率达84.2%。结论DDP化疗后肾功能轻度异常患者,再次采用含DDP方案化疗时,加用氨磷汀可以防止肾功能的进一步损害。 Objective To observe the protective effect of amifostine on the patients using cisplatin - based chemotherapy again,whose nephrotoxicity had been induced by cisplatin. Methods 19 patients whose renal function had been damaged by cisplatin received cisplatin -based chemotherapy again. Amifostine 250 mg/m^2 was used 30 minutes before injection of cisplatin. The indicators included blood urea nitrogen and creatinine being assayed before and after the chemotherapy to observe the amelioration of renal function. Results The total effective rate was 84.2% in the 19 patients, with CR 4 cases, SD 12 cases, PD 3 cases. Conclusion Amifostine used before cisplatin - based chemotherapy can protect the renal function having been damaged by cisplatin from further being destroyed.
出处 《实用癌症杂志》 2009年第4期386-387,410,共3页 The Practical Journal of Cancer
关键词 氨磷汀 肾脏毒性 顺铂 Amifostine Nephrotoxicity Cisplatin
  • 相关文献

参考文献4

二级参考文献66

  • 1卢学春,朱宏丽,姚善谦,范辉,庄晓萌,杨洋.氨磷汀联合重组人红细胞生成素治疗高龄骨髓增生异常综合征近期疗效观察[J].中国实验血液学杂志,2005,13(3):440-442. 被引量:20
  • 2卢学春,朱宏丽.氨磷汀治疗骨髓增生异常综合征研究进展[J].军医进修学院学报,2006,27(1):69-71. 被引量:9
  • 3范辉,朱宏丽,姚善谦,卢学春,庄晓萌,杨洋.氨磷汀治疗特发性血小板减少性紫癜高龄患者近期疗效观察[J].中国实验血液学杂志,2006,14(2):301-303. 被引量:16
  • 4[1]Hospers CAP, Eisanhauer EA , Vries de EGE, et al. The sulfhydryl containing compounds WR-2721 and glutathione as radio and chemoprotective agents: a review, indications for use and prospects [J]. Br J Cancer, 1999,80(5-6) :629-638.
  • 5[2]Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology: clinical practice guidelines for the use of chemotherapy and radiotherapy protectants [J]. J Clin Oncol,1999,171(10):3333-3353.
  • 6[3]Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissue from cytotoxic therapies by amifostine [J]. Semin Oncol, 1999,26 ( 2 Suppl 7 ):3-21.
  • 7[4]Sviles A, Diza Maqueo JC, Talavera A, et al. Protective of amifostine on hematopoiesi in lymphoma with high risk prognosis [J].Eur J Cancer, 1997,33(8): 1323-1325.
  • 8[5]Anderson Ⅱ, Mercer V, Thatcher N. A Phase Ⅲ randomized trial of carboplatin and amifostine versus carboplatin and G-CSF in patients with inoperable non-small-cell lung cancer [J]. Pro Am Soc Clin Oncol, 1998,17(2):465.
  • 9[6]Glover D, Glick JH, Weiler C, et al. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase Ⅱ trial [J]. Clin 0ncol,1986,4(4) :584-588.
  • 10[7]Kemp G, Rose P, Vurain J, et al. Amifostine pretreatment for protection against cyclophosphamfide-induced and cisplatin-induced toxicities results of a randomized control trial in patients with advanced ovarian cancer [J]. Clin Oncol,1996,14(7):2101-2112.

共引文献37

同被引文献49

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部